TGR BioSciences wishes to announce the transaction to facilitate the exit of the Nanyang Innovation Fund and Statewide Superannuation has been completed. The early investment by these shareholders was essential in assisting the Company to develop its current technologies. The Company is pleased that Management and other current shareholders were able to fund the exit transaction confirming their commitment to the Company’s business strategy.
TGR would like to recognise the substantial contribution and support given by all of its exiting shareholders. Further, the significant commitment by departing Directors John Bastian (Independent) and Simon Uzcilas (Nanyang) greatly assisted in completion of the transaction.
TGR BioSciences is a private company located in Adelaide, Australia. Established in 2001, TGR is committed to providing innovative solutions for cell-based research applications. Our scientists have expertise in cell biology, biochemistry and immunoassay design, and have developed products and services of the highest quality, which have been used successfully in drug discovery programs around the world.
For more information, contact;
Anne Hinton, CEO, TGR BioSciences
ahinton@tgrbio.com, +61 8 8354 6174
or
Andrew Sneddon, Chairman, TGR BioSciences